Fluditek, 2% syrup 125 ml

Pharmacodynamics

The mucolytic and expectorant action of Fluditek is due to the activation of sialic transferase – an enzyme of the mucous membrane of the bronchi. Normalizes the quantitative ratio of acidic and neutral sialomucin bronchial secretion, restores viscosity and elasticity of mucus. Contributes to the regeneration of the mucous membrane, normalizes its structure, activates the ciliated epithelium. Restores secretion of immunologically active IgA (specific protection) and the number of sulfhydryl groups of mucus components (nonspecific protection), improves mucociliary clearance.

Restores the secretion of immunologically active IgA (specific protection) and the number of sulfhydryl groups of mucus components (non-specific protection).

Pharmacokinetics

After oral administration Cmax in blood serum and in respiratory mucosa is reached after 2-3 hours and persists in mucosa for 8 hours. It is excreted mainly by the kidneys, partially – unchanged, partially – as metabolites.

Indications

– acute and chronic bronchopulmonary diseases, accompanied by the formation of viscous, difficult to separate sputum (tracheitis, bronchitis, tracheobronchitis, bronchial asthma, bronchiectasis);

– acute and chronic inflammatory diseases of the nasal cavity, nasopharynx, paranasal sinuses and middle ear, accompanied by the formation of viscous, difficult-to-discharge mucus (rhinitis, adenoiditis, sinusitis, otitis media);

— preparation for bronchoscopy and/or bronchography.

Pharmacological effect

Pharmacodynamics

The mucolytic and expectorant effect of Fluditec is due to the activation of sialic transferase, an enzyme of goblet cells of the bronchial mucosa. Normalizes the quantitative ratio of acidic and neutral sialomucins in bronchial secretions, restores the viscosity and elasticity of mucus. Promotes the regeneration of the mucous membrane, normalizes its structure, and activates the activity of the ciliated epithelium. Restores the secretion of immunologically active IgA (specific protection) and the amount of sulfhydryl groups of mucus components (nonspecific protection), improves mucociliary clearance.

Restores the secretion of immunologically active IgA (specific protection) and the amount of sulfhydryl groups of mucus components (non-specific protection).

Pharmacokinetics

After oral administration, Cmax in the blood serum and in the mucous membrane of the respiratory tract is reached within 2–3 hours and remains in the mucous membrane for 8 hours. It is excreted mainly by the kidneys, partially unchanged, partially in the form of metabolites.

Special instructions

Fluditec should be used with caution for wet coughs.

For persons with gastric and duodenal ulcers, the drug is recommended to be prescribed with caution.

The simultaneous use of Fluditec with antitussive drugs and/or substances that inhibit bronchial secretion (including atropine-like drugs) is not recommended.

When prescribing the drug for concomitant diabetes mellitus, as well as for patients on a low-sugar diet, the sucrose content should be taken into account (3.5 g per teaspoon in syrup for children).

Active ingredient

Carbocysteine

Composition

100 ml of syrup for children contains:

active ingredient:

carbocisteine ​​2 g;

excipients:

sucrose,

banana flavor,

methyl parahydroxybenzoate,

glycerin,

sodium hydroxide,

yellow-orange dye S,

purified water;

preservative:

methyl parahydroxybenzoate

Pregnancy

Contraindicated in the first trimester of pregnancy.

Contraindications

– peptic ulcer of the stomach and duodenum in the acute phase;
— chronic glomerulonephritis (in the acute phase), cystitis;
– children up to 2 years of age (for syrup 20 mg/ml for children) and up to 15 years (for syrup 50 mg/ml);
— I trimester of pregnancy (for syrup 50 mg/ml);
– hypersensitivity to carbocysteine ​​or other components of the drug Fluditec.

The drug should be prescribed with caution in case of chronic glomerulonephritis (history), gastric ulcer and duodenal ulcer (history).

Side Effects

From the gastrointestinal tract: sometimes – nausea, vomiting, diarrhea, epigastric pain, gastrointestinal bleeding.

Allergic reactions: in isolated cases – itching, urticaria, exanthema, angioedema.

From the nervous system and sensory organs: dizziness, weakness, malaise.

Interaction

When used together with GCS, a synergistic effect is observed.

Increases the effectiveness of antibacterial therapy for inflammatory diseases of the upper and lower respiratory tract.

Enhances the bronchodilator effect of theophylline.

The activity of carbocisteine ​​is weakened by antitussives and atropine-like drugs.

Overdose

Symptoms: gastralgia, nausea, diarrhea.

Treatment: symptomatic therapy.

Storage conditions

At room temperature

Shelf life

2 years

Manufacturer

Uniter Liquid Manufacturing, France